Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

ABSTRACT:

What is already known about this subject

* Pharmacokinetic variability of voriconazole is largely caused by CYP3A4- and CYP2C19-mediated metabolism. * Oral bioavailability of voriconazole has been claimed to be almost 100%, thus facilitating a change from intravenous to oral application without dose adjustment.

What this study adds

* For the first time voriconazole exposure after intravenous and oral administration in relation to CYP2C19 activity is reported. * In addition, the predominant metabolic pathway is the hydroxylation that seems to be influenced by the CYP2C19 genotype. * Enterohepatic circulation of both hydroxylated metabolites must be anticipated.

Aims

The aim was to determine the pharmacokinetics of voriconazole after a single oral dose in comparison wit

SUBMITTER: Scholz I 

PROVIDER: S-EPMC2810802 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature